Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Rillieux-la-Pape

2 clinical trials in Rillieux-la-Pape, France. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Rillieux-la-Pape at a glance
2
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 trials in Rillieux-la-Pape

Open in trial search

Colorectal cancer stage III

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Unicancer

Gastrooesophageal cancer+1

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:FRUQUINTINIB
  • Sponsor:Fondation Franc.Cancerologie Digestive

Other cities in France

The busiest research cities in the country

All 379 cities in France

Clinical research in Rillieux-la-Pape

What the registry says about research in the country

01 Rillieux-la-Pape
Metastatic Oeso‑Gastric Adenocarcinoma
A randomized trial in Rillieux‑la‑Pape is comparing a novel oral combo therapy with standard treatment to improve outcomes for patients with advanced gastric and esophageal tumors. Assessment of overall survival between the combination and monotherapy arms. Evaluation of trifluridine/tipiracil + fruquintinib as a targeted regimen. Investigation of safety and quality‑of‑life benefits. Collaboration between two local research sites. Results aim to define a new standard for metastatic oeso‑gastric adenocarcinoma and could expand therapeutic options in Europe.
Stage III Colorectal Cancer – ctDNA Guided Chemotherapy
In Rillieux‑la‑Pape, researchers are testing blood‑based stratification to personalize adjuvant chemotherapy after surgical removal of stage III colon tumors. Use of ctDNA status to assign patients to de‑escalation or escalation arms. Non‑inferiority trial of 6‑month capecitabine alone versus 3‑month capecitabine + oxaliplatin. Superiority trial of 6‑month FOLFIRINOX versus 6‑month FOLFOX in ctDNA‑positive patients. Primary focus on 3‑year disease‑free survival as the efficacy endpoint. Findings could reshape standard adjuvant therapy by matching intensity to residual molecular risk.
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.